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Abstract 
Background: Characterizing the genetic diversity of malaria parasite populations in different endemic settings (from 
low to high) could be helpful in determining the effectiveness of malaria interventions. This study compared Plas-
modium falciparum parasite population diversity from two sites with low (pre‑elimination) and high transmission in 
Senegal and Nigeria, respectively.
Methods: Parasite genomic DNA was extracted from 187 dried blood spot collected from confirmed uncomplicated 
P. falciparum malaria infected patients in Senegal (94) and Nigeria (93). Allelic polymorphism at merozoite surface pro-
tein 1 (msp1) and merozoite surface protein‑ 2 (msp2) genes were assessed by nested PCR.
Results: The most frequent msp1 and msp2 allelic families are the K1 and IC3D7 allelotypes in both Senegal and 
Nigeria. Multiplicity of infection (MOI) of greater that 1 and thus complex infections was common in both study sites 
in Senegal (Thies:1.51/2.53; Kedougou:2.2/2.0 for msp1/2) than in Nigeria (Gbagada: 1.39/1.96; Oredo: 1.35/1.75]). 
The heterozygosity of msp1 gene was higher in P. falciparum isolates from Senegal (Thies: 0.62; Kedougou: 0.53) than 
isolates from Nigeria (Gbagada: 0.55; Oredo: 0.50). In Senegal, K1 alleles was associated with heavy than with moder‑
ate parasite density. Meanwhile, equal proportions of K1 were observed in both heavy and moderate infection types 
in Nigeria. The IC3D7 subtype allele of the msp2 family was the most frequent in heavily parasitaemic individuals from 
both countries than in the moderately infected participants.
Conclusion: The unexpectedly low genetic diversity of infections high endemic Nigerian setting compared to the 
low endemic settings in Senegal is suggestive of possible epidemic outbreak in Nigeria.
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Background
Malaria caused by Plasmodium falciparum continues 
to be a significant public health havoc in many endemic 
countries in tropical and sub-tropical parts of the world 
[1]. Though preventable, malaria accounted for 228 mil-
lion cases and a mortality of 405,000, in 2018 alone [2]. 
During same period, the African region contributed a 
significant proportion of falciparum malaria cases (93%) 
and mortality (94%) [2]. Though, progress has been 
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observed in malaria control, but in recent time there has 
been a plateau in advancement.
Malaria in Africa, majorly cause by P. falciparum con-
tinues to affect almost all age groups at risk of the dis-
ease in endemic areas. Senegal and Nigeria are both 
located in western part of Africa with different levels of 
interventions, heterogeneity in endemicity and transmis-
sion. In Senegal, malaria prevalence is generally low but, 
the entire population remain at risk and transmission 
increases gradually from the northern to the Southern 
part, corresponding to hyperendemicity from the south 
(annual incidence > 100/1000 inhabitants) to hypoende-
micity in the North (annual incidence < 5/1000 inhabit-
ants), respectively [3]. In 2017, malaria accounted for 
395 706 cases, 284 deaths and by 33.45% among chil-
dren under 5 in Senegal [4], despite intensified malaria 
control over the last 10  years. While malaria endemic-
ity in Nigeria varies between the six geo-political zones 
of the country, with south west having a mix of meso- 
and hypo-endemic (1–50%) situation, the south south, 
south east, north east and north central uniformly hypo-
endemic (20–39%), while the north western part being 
largely meso-endemic (40–49%). Annually, 40% of Nige-
ria gross domestic product is spent on malaria control 
[5], yet the country contribute about 25% of annual global 
incidence rates.
Hence, an effective malaria vaccine that can be readily 
available to at risk individuals in endemic areas remains 
imperative. Nevertheless, this initiative is being impeded 
by the enormous parasite diversity [6–8], which renders 
the vaccine almost ineffective in some populations. RTS, 
S, the only malaria vaccine gives a 30% protection even 
with multiple booster doses. This has mostly been attrib-
uted to the genetic diversity of the parasite, which also 
affects drug efficacy.
In moderate and high transmission areas such as in 
Africa, the probability of a person being infected with 
numerous parasite clones at the same time is very high 
[9–13]. These clones/strains are often a reflection of the 
transmission intensity or endemicity of an area and as 
such, impacts the immune system of persons residing 
in endemic regions. Ultimately, the interplay between 
parasite clones and the immune selective pressure has a 
profound impact on the success of any approved vaccine. 
Therefore, characterization of malaria parasite popula-
tions in different endemic settings (from low to high), 
becomes much more needed to help in the development 
of a second-generation vaccines and monitor current 
interventions. The asexual blood stage antigens merozo-
ite surface protein 1 and 2 (MSP1 and MSP2) along with 
the glutamate-rich protein (GLURP) are highly diverse 
antigens being exploited for vaccine advancement [14, 
15]. However, they have also been used in various studies 
in evaluating the different circulating clones of P. falci-
parum and/or determining the impact and progress of 
malaria intervention [16, 17].
The objective of this study was to compare repeat 
length polymorphism and genetic diversity of P. falcipa-
rum isolates from Nigeria and Senegal using the msp1 
and msp2 genes. In addition, the multiplicity of infection 
and heterozygosity, both of which reflect the transmis-
sion intensity as affected by intervention were evaluated.
Methods
Ethical consideration
The study from Nigeria was approved by the Institutional 
Review Board (IRB/16/347), Nigerian Institute of Medi-
cal Research, Lagos and Lagos State Health Service Com-
mission. Ethical approval for Senegal was obtained by by 
the National Ethics Committee for Health Research of 
Senegal. In addition, written and/or verbal consent where 
applicable were obtained from all recruited participants.
Study sites and samples collection
This study was carried out in two West African countries: 
Nigeria and Senegal.
In Nigeria, isolates were collected in two Local Govern-
ment Areas of Lagos states namely Kosofe (06° 28′ N 003° 
22′ E) and Ikorodu (06° 33′ N 003° 35′ E) from December 
2016–March, 2017. Description of study area has been 
done in an earlier study [18]. Briefly, Lagos state shares 
a border with the Republic of Benin and is hypo-endemic 
in most part with a 1.9% prevalence rate in children age 
6–59  months [19]. This is in part due to the expansion 
of insecticide-treated nets (ITNs) coverage, and active 
indoor residual spraying (IRS) in many of its LGAs [20].
In Senegal, samples were collected in two areas with 
different endemicity levels, Kedougou located in the 
south-east and Thiès in western Senegal in 2016. In 
Kedougou, malaria transmission is seasonal from July 
to December, with an entomological inoculation rate 
(EIR) of 20 to 100 infectious bites/person/year and an 
incidence > 25 malaria cases per 1000 habitants. While 
in Thies, the malaria situation is hypo-endemic, with an 
average 0–20 infectious mosquito bite annually and an 
incidence of 5–15 malaria cases per 1000 habitants. The 
malaria seasonal transmission in this area coincides with 
rainy season which generally last up to 4  months (Sep-
tember to December) [3, 21].
In both countries, a purposeful sampling was employed 
and only febrile patients (94 from Senegal and 93 from 
Nigeria) visiting health facilities in these areas during 
malaria transmission season were recruited. Blood sam-
ples were collected on filter-paper from patients who met 
the following inclusion criteria: residence 15-km radius 
of health facilities, presence of febrile condition (axillary 
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temperature ≥ 37.5 °C) in the previous 48 h, age ranging 
from 6 months to 75 years and uncomplicated P. falcipa-
rum malaria with parasite density ≥ 1000 asexual forms 
per microlitre. Patients who presented signs or symptoms 
of severe malaria as defined by World Health Organiza-
tion (WHO) [2] and pregnant women were not included.
“Pre‑molecular” sample processing
Care  Start® P.f (Access Bio Inc, USA) malaria RDT was 
used to initially detect P. falciparum following the manu-
facturer’s instruction, and samples found positive were 
processed for microscopy. Thin and thick blood films 
were prepared for each patient’s sample following a pre-
viously described protocol [20]. Positive Giemsa stained 
thick smear were counted against a minimum of 500 
leucocytes and parasite density(PD) estimated using the 
8000 white blood cells (WBCs)/ul following the formula 
below:
PD = (estimated parasite count × 8000)/number WBCs
PD was further classified into low (> 500 parasite/µl), 
moderate (500–< 1000 parasite/µl) and high PD (> 1000 
parasite/µl) as per the World Health Organization clas-
sification system.
Molecular sample processing: parasite DNA extraction, 
species and allelic typing of P. falciparum msp1 and msp2 
genes
Parasite genomic DNA was extracted from filter paper 
using QIAamp DNA Mini kit (QIAGEN, USA) according 
to the manufacturer’s instructions. Confirmation of P. fal-
ciparum isolates was done following the Snonou protocol 
[21] that targets the 18S rRNA of P. falciparum isolates. 
PCR amplification was carried out in a total volume of 
25 µl with 1 µl of extracted DNA and 2 µl of nest 1 ampli-
con for the primary and nested PCR respectively using 
the Gotaq Green Master mix (Promega) as detailed in 
an earlier work [16]. Only confirmed P. falciparum (cor-
responding to 205 bp fragment size) were processed for 
the polymorphic loci genotyping of P. falciparum msp1 
block 2 (K1, MAD20 and RO33) and msp2 central region 
(IC3D7 and FC27) following a previously described 
nested PCR protocol [22, 23] (Additional file 1: Table S1). 
All PCR reactions were carried out in a final volume of 
20 μl containing: 1 μl of gDNA, 6 μl GoTaq Green Master 
Mix (Promega), 1 μl (0.5 μM) of each primer, and 11 μl 
nuclease free water. In both rounds of reaction, 1  μl of 
gDNA and PCR amplicon were used respectively as tem-
plates for nest 1 and 2 amplifications.
Cycling conditions for both PCR were as follows: initial 
denaturation at 95 °C for 5 min, followed by 35 cycles of 
denaturation at 94  °C for 1  min, annealing at 58  °C for 
2 min (61 °C for 2 min for the nested reaction) and exten-
sion at 72 °C for 2 min; a final extension was carried out 
at 72 °C for 3 min. Positives (3D7 and Dd2) and negative 
(DNase free water) controls were systematically incorpo-
rated in each PCR run.
The nested PCR product were resolved in 2% agarose 
gels electrophoresis stained with ethidium bromide and 
visualized under UV trans-illumination  (VersaDoc®, Bio-
Rad, Hercules, USA). The sizes of PCR fragments were 
estimated using 100 bp molecular weight ladder (Maker). 
Presence of more than one genotype was taken as a poly-
clonal infection, while a single allele was considered as 
a monoclonal infection. If fragment sizes were within a 
20 bp interval, alleles in each family were considered the 
same [24].
Statistical analysis
The online Biostatgv was used for statistical analysis. The 
Chi square test (χ2) was used to compare the frequen-
cies of multiclonal isolates between sites and countries. 
The mean multiplicity of infection (MOI) was calculated 
as the quotient of the total number of genotypes for 
each marker and the number of PCR-positive samples. 
Thus, MOI was calculated by dividing the total number 
of alleles detected for msp1 and msp2 genes by the total 
number of samples [25]. Student’s t test was used to com-
pare MOI between sites.
The expected heterozygosity (He, which is a measure 
of genetic diversity) was employed to assess population 
structure of parasites. Heterozygosity was calculated 
using the following formula He = [n/(n − 1)] [(1 − ΣPi2)], 
where n = sample size, Pi = allele frequency as described 
by [26]. A p value of ≤ 0.05 was considered suggestive of a 
statistically significant difference.
Results
A total of 187 malaria infected participants were 
recruited for the study with almost equal proportion 
from the two countries (94 from Senegal and 93 from 
Nigeria). The mean age was not different from each coun-
try and locality within the countries. Although, partici-
pants were randomly enrolled into the study, however, 
more males (108) partook in the study than females (79) 
(Table 1).
Genetic polymorphism of msp1 and msp2 genes in Senegal 
and Nigeria
For msp1, gene diversity from the two countries were 
similar. K1 allelic family was predominant in Senegal and 
Nigeria with frequencies of 44% and 48%, respectively. 
RO33 allelic family was less represented in the both 
country with the frequency of 6% in Senegal and 15% in 
Nigeria. For polygenomic (complex) infections, K1/RO33 
combination was the most frequent in both countries but 
higher in Senegal (17%), and Nigeria (7%). However, the 
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K1/MAD20/RO33 trimorphic allelic infections were least 
frequent; Senegal (3%) and Nigeria (2%).
The fragment size of K1 allele type observed in Senegal 
(100-350  bp) was different from that seen in P. falcipa-
rum isolates from Nigeria (190-300  bp). Similar pattern 
was also observed with the MAD20 alleles, where sizes in 
Senegal ranged from 100-300 bp while those from Nige-
ria ranged from 200 to 300  bp. In addition, a different 
pattern was observed in RO33 where only one clone type 
was seen in Nigeria (160 bp) as against multiple clones in 
Senegal (160–240 bp) (Fig. 1a, b).
For msp2 gene, there was no difference in the fre-
quency of isolates with IC3D7 allele in Senegal (57%) 
and Nigeria (58%), while the FC27 frequency was more 
prevalent in Senegal (26%) than in Nigeria (16%). Simi-
lar pattern was noticed with the IC3D7/FC27 dimor-
phic allelic family in both countries. Allele sizes of the 
IC3D7 variant of msp2 ranged from 300 to 700  bp in 
Senegal and 300–800  bp in Nigerian P. falciparum 
isolates, while FC27 alleles varied in size from 200 to 
600 bp in Senegal and 290–550 bp in Nigeria (Fig. 1c, 
d).
Table 1 Characteristics of the study participants in four different endemic sites located in the two West African countries
PD parasite density
Variables Senegal Nigeria
Thies Kedougou Kosofe Ikorodu
Number (%) 47 (50) 47 (50) 29 (31.2) 64 (68.8)
Mean age (± SD) 26.8 (15.2) 20.4 (13.7) 24 (14.4) 27.8 (18.7)
PD (parasite/μl) mean 
(range) (Min–max)
27,411.7 (900–164,700) 35,348.9 (1350–207,000) 37,673.9 (34–584,000) 24,981 (149–905,600)
Male 41 (87.2) 23 (48.9) 16 (55.2) 28 (43.8)
Female 6 (12.8) 24 (51.1) 13 (44.8) 36 (56.2)
a b
c d
Fig. 1 Prevalence of MSP 1 and 2 allele fragment sizes of P. falciparum; msp 1 in a Senegal, b Nigeria, and msp 2 in c Senegal, d Nigeria
Page 5 of 8Oboh et al. Malar J           (2021) 20:38  
Multiplicity of P. falciparum infection and heterozygosity 
of msp1 and msp2
The presence of multiple clones in a single infection 
define by the MOI index was higher in both study sites in 
Senegal (Thies, 1.51/2.53; Kedougou, 2.2/2.0 for msp1/2) 
than the sites in Nigeria (Gbagada, 1.39/1.96; Oredo, 
1.35/1.75). Consequently, the heterozygosity of msp1 
gene was higher in P. falciparum isolates from Senegal 
(Thies, 0.62; Kedougou, 0.53) than isolates from Nigeria 
(Gbagada, 0.55; Oredo, 0.50). However, the heterozygo-
sity of msp2 gene was not different for the two countries 
(Table 2).
Genetic polymorphism of msp1 and msp2 genes 
by parasite density
The distribution of various allele types in both msp1 and 
2 in individuals infected with different parasite densities 
showed some level of stratification. For msp1 allele type, 
K1, MAD20, RO33 and their various allele combinations 
were not amplified in individuals with low parasitaemia 
infections (50–499 parasites/µl) from both countries. The 
K1 allele was more prevalent in individuals with higher 
parasitaemia infections (28) than those with moder-
ate infections (18) from Senegal. However, in Nigeria, 
equal proportions of K1 were present in both moderate 
and high parasitaemic infections. Individuals with heavy 
infections from Senegal showed the highest proportion 
of K1/MAD20 (14) allele combination and same pattern 
was observed for the K1/RO33 mixture (13).
The IC3D7 subtype allele of the msp2 family showed 
high occurrence in high parasitaemic individuals from 
both countries (Senegal, 32; Nigeria, 26) than in the mod-
erately infected participants. Similar pattern was noticed 
with the FC27 allele (Fig. 2a, b).
Discussion
Control interventions targeting malaria parasite contin-
ues to face multiples hurdles from development of drug 
resistance in the parasite, insecticide resistance by the 
vectors, and unavailability of a reliable vaccine to con-
fer the necessary protection against the parasite. Hence, 
there is need for continuous monitoring and evalua-
tion of the effectiveness of control measures. Here, the 
Table 2 Multiplicity of  infection and  heterozygosity 
of  msp1 and  msp2 of  P. falciparum from  Senegal 
and Nigeria
MOI multiplicity of infection, He heterozygosity
* p-value less than 0.05 significant
Gene Senegal Nigeria p‑value
Thies Kedougou Gbagada Oredo
msp1
 MOI 1.51 2.2 1.39 1.35 0.00*
 He 0.62 0.53 0.55 0.50 0.89
msp2
 MOI 2.53 2.00 1.96 1.75 0.39
 He 0.48 0.44 0.47 0.48 0.77
 MOI (both 
genes)
2.65 2.68 1.64 1.57 0.72
Fig. 2 a Genetic diversity of P. falciparum msp1 and msp2 stratified by parasite density in infected individuals from Senegal. b Genetic diversity of P. 
falciparum msp1 and msp2 stratified by parasite density in infected individuals from Nigeria
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diversity of P. falciparum msp 1 and msp 2 from malaria 
infected individual’s resident in two West African coun-
tries with significantly different levels of overall parasite 
endemicity; hypo-endemic area in Senegal and a meso-
hyper endemic area of Nigeria was evaluated. Multiplicity 
of infection (MOI) index which is related to the number 
of clones per infection and usually associated with the 
level of malaria transmission [27–29] was also calculated. 
High MOI for both the msp1 and 2 genes were observed 
for both study locations in Senegal, but moderate MOI 
values were noted in Nigeria. Similar results for Senegal 
were reported by Niang et al. in 2017 [29]. This observa-
tion is unexpected as Senegal is generally categorized as 
a country under the malaria pre-elimination stage and 
as such, moderate to low MOI levels were expected. This 
could have several implications for the malaria control 
programme in Senegal: firstly, as control managers tar-
get a more focal control, parasite could be circulating 
and transmission going on in other not-targetted areas, 
subsequently, this high MOI observed and if neglected 
could lead to extensive parasite recombination and hence 
further diverse falciparum strains that could pose prob-
lems in employing the conventional control methods (use 
of artemisinin combination therapy). While Nigeria with 
more intense transmission across all regions should usu-
ally show high levels of MOI. However, the detection of 
low-moderate level of MOI in Nigeria shows that though 
transmission is high, but same clones of parasites are cir-
culating the area. Hence, similar control strategy can be 
planned and implemented in the areas. Although, cau-
tion is needed when interpreting such results as samples 
were only collected from western Nigeria. Transmis-
sion of malaria in Kedougou is highest in Senegal and 
this region borders high transmission countries such as 
Mali and Guinea. On the other hand, the sites in Nige-
ria from the southern region are in proximity to the large 
Lagos metropolis where malaria prevalence is relatively 
low compared to the rest of the country. Low complex-
ity infections have been reported in low prevalence urban 
dwellings across Africa.
Based on heterozygosity, which measures the level of 
genetic diversity at polymorphic loci, msp1 was more 
diverse in infections from Senegal than those from Nige-
ria. However, similar levels of diversity for msp2 was 
observed in both countries. This is in line with the differ-
ences in MOI probably due to differences in urbanization 
levels and recombination between genetically different 
clones. Indeed, there was a difference in the clonal struc-
tures of all allelic families (K1, MAD20, 3D7 and FC27) 
from both countries with Senegal showing the more 
sub-structured msp1 and msp2 populations. Neverthe-
less, similar trends has been observed in the Kingdom of 
Eswatini where a high genetic diversity was obtained in a 
low transmission area [30]. Circulation of different frag-
ment sizes of K1 alleles in both countries is indicative of 
the presence of distinct falciparum clones occurring in 
both countries. Taken together, this result underscores 
the need for a more comprehensive evaluation of trans-
mission using different epidemiological tools.
The high occurrence of msp1 K1 allele in high and low 
parasite infections from both countries has been previ-
ously observed by various studies [31], with this alleles 
associated more with these levels of parasite density. 
Whether the high parasite density is driving the selec-
tion of K1 or vice versa is yet to be determined. The 
strong presence of this allelic families was reported by 
many studies carried out in West Africa [28, 32], western 
Uganda [33] and Iran [34].
Similarly, high frequency of IC3D7 allele type of msp2 
gene was also observed with both grades of parasite den-
sity, while no particular pattern was noticed with the 
FC27 allelotype. This finding is in agreement with the 
study of Hamid et  al. in 2013 [35] where IC3D7 alleles 
was more predominant in moderate and heavily infected 
individuals.
Conclusion
Taken together, it can be concluded that evidence driv-
ing selection of these observed allelotypes in moderate 
and heavy P. falciparum individuals should be evaluated 
in a bidirectional manner and a more holistic approach 
should be employed in determining the true epidemio-
logical situation of any malaria endemic country as this 
will help in a more targeted control measure.
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